| Factor Information | |
|---|---|
| Data ID | 3681 |
| Factor | nitric oxide (NO) |
| Description | ADM and ET-1 levels in moderate or severe-PH groups were increased as compared with those in mild-PH group (both P<0.01), but NO level significantly declined (P <0.05). |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The changes of ADM, ET-l and NO levels before and after operation in CHD associated with PH were observed in Order to investigate their role in CHD with PH and their clinical significance. |
| p Value | <0.05 |
| Conclusion | It was concluded that during the progression of PH in the cases of CHD, plasma ADM, ET-1 and NO might play an important role in the development of PH. The increased ADM may represent a compensatory mechanism. It can interact with NO and ET-1 to regulate pulmonary circulation in the pathophysiology of PH with CHD. ADM may be involved in the defence mechanism against further increase of pulmonary arterial pressure. ADM could be used as a reliable indicator of the severity of CHD associated PH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 390 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/ASD/PDA |
| Reference | |
|---|---|
| PMID | 14526432 |
| Year | 2003 |
| Title | Role of adrenomedullin in congenital heart disease associated with pulmonary hypertension. |
| Sample | ||
|---|---|---|
| Population | Children | |
| Source | Plasma | |
| Region | Wuhan, China | |
| Method | radioimmunoassay and colorimetry methods. | |
| Race | Asian | |
| Disease History | pulmonary hypertension | |
| Treatment History | N/A | |
| Group | Moderate or severe-PH(pulmonary artery systolic pressure, PASP> 50 mmHg)(Treatment) | Non-PH (pulmonary artery systolic pressure, PASP <30 mmHg)(Control) |
| Number | 12 | 11 |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 55.04±17.02 mmol/L | 68.68±12.32 mmol/L |
